Page 1

PILL Proteomics International LABORATORIES LTD ASX Release 28 October 2021 ASX code : PIQ Quarterly Activities Report Proteomics International Laboratories Ltd ( Proteomics International ; ASX : PIQ ) , a medical technology company at the forefront of precision medicine and predictive diagnostics , is pleased to provide the following update on its business activities for the three months to 30 September 2021 and subsequent to the period end . This has been a highly significant quarter for the Company , with four pivotal milestones achieved : Diabetes treatment lowers PromarkerD risk score ( Janssen Stage 2 results ) : Proteomics International has previously published the results of several studies showing that its PromarkerD test can predict future kidney function decline in patients with type 2 diabetes and no existing diabetic kidney disease ( DKD ) . Now , for the first time , strong positive results from a study with US pharmaceutical company Janssen have shown that the gliflozin class drugs offer a new treatment option for these at - risk patients . Northern Hemisphere manufacturers engaged for PromarkerD immunoassay test : Proteomics International has implemented global manufacturing standards for the production of the PromarkerD assay and engaged manufacturing specialists Biotem and Abcam to enable large scale production of the test as global sales grow . Clinical utility study demonstrates benefit of PromarkerD testing : Results presented to a conference of US insurance companies and payors have demonstrated PromarkerD's appeal to clinicians in the management of diabetic kidney disease . This clinical utility study will also form a valuable part of the information dossier to support Proteomics International's application for a unique US reimbursement code for PromarkerD . Promarker diagnostics pipeline advances - Collaboration to develop test for endometriosis : Proteomics International's rich pipeline of new intellectual property in development was exemplified by a partnership with the University of Melbourne and the Royal Women's Hospital to advance the Company's potential new blood test for endometriosis . Proteomics International's portfolio of other diagnostic tests in development also continues to mature . Proteomics International continues to see growth opportunities on multiple fronts across its portfolio of activities and includes its 2021-22 outlook for several major areas below . OPERATIONAL HIGHLIGHTS Proteomics International's activities fall into three key areas : ( i ) commercialisation of PromarkerD , the predictive test for diabetic kidney disease ( DKD ) ( ii ) R & D for new diagnostic tests using the Promarker ™ pipeline ( iii ) analytical services on a commercial basis Part of the PILL Group Proteomics International Laboratories Ltd ABN 78 169 979 971 Box 3008 , Broadway , Nedlands , WA 6009 , Australia T : +61 8 9389 1992 | E : enquiries@proteomicsinternational.com | W : www.proteomicsinternational.com 1/6